cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this ancillary clinical trial is to evaluated circulating DNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carninoma. The main question it aims to answer is : \- Does circulating DNA (cDNA) be able to detect residual disease 3 months after the end of chemoradiotherapy ? Researchers will compare detection of cDNA at 3-months and objective response (clinical and radiological). Participants will : * be included in the main study (Neck-TAR) * have a blood sample 1 and 3-month after the end of treatment
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Uczestnictwo w głównym badaniu NeckTAR
- •Podpisana świadoma zgoda na uczestnictwo w badaniu NeckTAR-IN
- •Członkowstwo w francuskim systemie ubezpieczenia społecznego
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 80 Years
- Last updated (source)
- July 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (4)
CH Henri Mondor Aurillac
Aurillac, France
Centre Jean PERRIN
Clermont-Ferrand, France
Hôpital de la Croix-Rousse
Lyon, France
CHU de Saint-Étienne
Saint-Etienne, France
Trial contact
Angeline GINZAC COUVÉ Project manager, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.